期刊文献+

伏立诺他合成路线图解 被引量:3

Graphical Synthetic Routes of Vorinostat
原文传递
导出
摘要 伏立诺他(vorinostat,1),化学名为Ⅳ-羟基-N’-苯基辛二酰胺,是美国默克公司开发的首个组蛋白去乙酰化酶抑制剂,2006年10月美国FDA批准上市,用于治疗持续、恶化或在用其他药治疗期间或之后复发的皮肤T细胞淋巴瘤(CTCL),商品名Zolinza。本品可在纳摩尔浓度下抑制组蛋白去乙酰化酶,造成肿瘤细胞转录过程异常,进而诱导肿瘤细胞周期停止、分化甚至死亡。
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2013年第3期303-305,共3页 Chinese Journal of Pharmaceuticals
基金 国家自然科学基金(21172134) 山东大学自主创新基金(2012JC003)资助
  • 相关文献

参考文献17

  • 1Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases [J]. Proc Natl Acad Sci U S A, 1998, 95 (6) : 3003-3007. 被引量:1
  • 2Marks PA. Discovery and development of SAHA as an anti- cancer agent [J]. Oncogene, 2007, 26 (9) : 1351-1356. 被引量:1
  • 3Butler LM, Agus DB, Scher HI, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, su- ppresses the growth of prostate cancer cells in vitro and in vivo [J]. Cancer Res, 2000, 60 (18) : 5165-5170. 被引量:1
  • 4Stowell JC, Huot RI, Voast VL. The synthesis of N-hydroxy- N'-phenyloctanediamide and its inhibitory effect on proliferation of AXC rat prostate cancer ceils [J]. J Med Chem, 1995, 38(8) : 1411-1413. 被引量:1
  • 5Kim C, Shah BP, Subrarnaniarn P, et al. Synergistic inductionof apoptosis in brain cancer cells by targeted codelivery of siRNA and anticancer drugs [J]. Mol Pharm, 2011, 8(5): 1955-1961. 被引量:1
  • 6Bacopoulos NG, Chiao JH Miller TA, et al. Methods of treating cancer with HDAC inhibitors: US, 20040127523 [P]. 2004-07-01. 被引量:1
  • 7周忻.组蛋白去乙酰化酶抑制剂SAHA的合成研究[J].海南医学院学报,2010,16(10):1259-1260. 被引量:2
  • 8Mai A, Esposito M, Sbardella G, et al. A new facile and expeditious synthesis of N-hydroxy-N'-phenyloctanediamjde, a potent inducer of terminal cytodifferencntiation [J]. Org Prep Procedlnt, 2001, 33 (4) : 391-394. 被引量:1
  • 9Leblond B, Beausoleil E. Tricyclic hydroxarnate and benz- amide derivatives, compositions and methods: EP, 1541549 [P]. 2003-12-12. 被引量:1
  • 10胡杨,陈国华,吴燕,杨尚彦.伏立诺他的合成[J].中国医药工业杂志,2009,40(7):481-483. 被引量:6

二级参考文献23

  • 1Richon VM, Emiliani S, Verdin E, et al. A class of hybridpolar inducers of transformed cell differentiation inhibits histone deacetylases [J]. Proc Natl Acad Sci USA, 1998, 95 (6) : 3003-3007. 被引量:1
  • 2Mark PA. Discovery and development of SAHA as an anticancer agent [J]. Oncogene, 2007, 26 (9) : 1351-1356. 被引量:1
  • 3FDA Approves New Drug for Skin Cancer, Zolinza [EB/OL]. [2006-10-06]. http://www.fda.gov/bbs/topics/ news/2006/new01484.html. 被引量:1
  • 4Breslow R, Marks PA, Rifkind BA, et al. Novel potent inducers of terminal differentiation and methods of use thereof: WO, 9307148 [P]. 1993-04-15. 被引量:1
  • 5Stowell JC, Huot RI, van Voast L, et al. The synthesis of N-hydroxy-N'-phenyloctanediamide and its inhibitory effect on proliferation of AXC rat prostate cancer cells [J]. J Med Chem, 1995, 38(9): 1411-1413. 被引量:1
  • 6Sbardella EG, Massa S. A new facile and expeditious synthesis of N-hydroxy-N'-phenyloctanediamide, a potent inducer of terminal cytodifferentiation [J]. OrgPrep Proced lnt, 2001, 33 (4) : 391-394. 被引量:1
  • 7Gediya LK, Chopra P, Purushottamachar P, et al. A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells [J]. J Med Chem, 2005, 48(15): 5047-5051. 被引量:1
  • 8Sakajiri S,Kumagai T,Kawamata N,et al.Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines[J].Exp Hematol,2005,33(1):53-61. 被引量:1
  • 9Cohen LA,Marks PA,Rifkind RA,et al.Suberoylanilide hydroxamic acid (SAHA),a histone deacetylase inhibitor,suppresses the growth of carcinogen-induced mammary tumors[J].Anticancer Res,2002,22 (3):1497-1504. 被引量:1
  • 10Breslow R,Marks PA,Rifkind RA,et al.Novel potent inducers of terminal differentiation and methods of use thereof:WO,9307148[P].1993-04-15.(CA 1993,119:138765) 被引量:1

共引文献8

同被引文献8

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部